Haematological malignancies: at the forefront of immunotherapeutic innovation.

Autor:	Bachireddy P; 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA., Burkhardt UE; Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA., Rajasagi M; 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Bristol-Meyers Squibb, Princeton, New Jersey 08540, USA., Wu CJ; 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Jazyk:	angličtina
Zdroj:	Nature reviews. Cancer [Nat Rev Cancer] 2015 Apr; Vol. 15 (4), pp. 201-15. Date of Electronic Publication: 2015 Mar 19.
DOI:	10.1038/nrc3907
Abstrakt:	The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF